FDA approves Merck’s sNDA for Recarbrio to treat HABP/VABP
FDA indicated Recarbrio for patients aged 18 years or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Jun 20
FDA indicated Recarbrio for patients aged 18 years or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia…
05 Jun 20
Daratumumab SC, administered as a fixed-dose, would reduce treatment time compared to daratumumab intravenous (IV) formulation
04 Jun 20
The regulatory approval is based on the Phase 3 BEACON CRC trial, which showed positive results for BRAFTOVI…
03 Jun 20
Philips’ new patient monitoring solutions will support infection-control protocols and remotely provide critical patient information for caregivers
02 Jun 20
The new indication expands Brilinta treatment to high-risk coronary patients without a history of stroke or heart attack
01 Jun 20
Janssen’s investigational Ebola vaccine regimen leverages its AdVac and PER.C6 technologies and Bavarian Nordic’s MVA-BN technology
01 Jun 20
Tecentriq plus Avastin is the only cancer immunotherapy regimen approved for the treatment of metastatic hepatocellular carcinoma
29 May 20
FDA indicated TAUVID for PET imaging of brain to assess the density and distribution of NFTs in patients…
28 May 20
With the EC approval, Zeposia becomes the only approved S1P receptor modulator available for the treatment of RRMS…
27 May 20
The safety and efficacy of artesunate was primarily evaluated in a randomised controlled trial in Asia and a…